Objective: To analyze hypersensitivity reactions to carboplatin and paclitaxel in patients treated with systemic administration of chemotherapy (carboplatin and/or paclitaxel). Conclusion: HSR to carboplatin is unlike paclitaxel affected by the number of administered cycles.
This fact should be included in the clinical management of patients treated with intravenous chemotherapy using carboplatin.